Pelthos Therapeutics revenue was $51.29M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2026) ending on Sep 30, 2026 was $15.4M, down 1.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PTHS annual revenue was $16.8M, with Infinity% growth year-over-year.
PTHS past revenue growth
How has PTHS's revenue growth performed historically?
On Nov 12, 2026, Pelthos Therapeutics (NYSEMKT: PTHS) reported Q3 2026 revenue of $15.40 million up 107.87% year over year. In the same quarter last year, Pelthos Therapeutics's revenue was $7.41 million.
What was Pelthos Therapeutics's revenue in 2025?
Pelthos Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $16.80 million, a Infinity% increase year over year.
How much does Pelthos Therapeutics make in a day?
Based on Pelthos Therapeutics annual revenue for the past five years, PTHS makes an average of $9,202.74 per day.
What was Pelthos Therapeutics's annual revenue growth in the past year?
As of Q4 2026, Pelthos Therapeutics's revenue has grown 592.59% year over year. This is 513.54 percentage points higher than the US Biotechnology industry revenue growth rate of 79.05%. Pelthos Therapeutics's revenue in the past year totaled $51.29 million.
How much does Pelthos Therapeutics make in a year?
Pelthos Therapeutics's revenue by year for the past five years is:
Pelthos Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $16.80 million, a Infinity% increase year over year.
Pelthos Therapeutics's annual revenue for Dec 31, 2024 was $0.00, a N/A decrease from 2023.
Pelthos Therapeutics's annual revenue for 2023 was $0.00, a N/A decrease from 2022.
Pelthos Therapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Pelthos Therapeutics's annual revenue for 2021 was $0.00, a 100% decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.